@techreport{oai:kindai.repo.nii.ac.jp:00019770,
 author = {林, 秀敏},
 month = {},
 note = {研究成果の概要（和文）：EGFR-TKIに耐性を示した後にﾆﾎﾞﾙﾏﾌﾞを使用したEGFR変異陽性非小細胞肺がん25例(T790M変異陽性8例)の有効性および免疫関連因子を検討した。陰性症例は陽性と比較して良好な有効性及び、PD-L1が高発現の傾向を示した。ﾆﾎﾞﾙﾏﾌﾞ使用症例9例の全ｴｸｿｰﾑ解析にてnon-synonymous mutation数を評価したところ、奏効例では有意にmutation数が高値であった。EGFR-TKI耐性症例に関しての耐性機序毎の抗PD-1抗体の有効性やnon-synonymous mutationを評価した初の報告であり、Annals of Oncology誌にて報告した。
研究成果の概要（英文）：The efficacy of PD-1 blockade in EGFR mutated NSCLC with different mechanisms of acquired resistance to EGFR-TKIs is unknown. We retrospectively evaluated nivolumab efficacy and immune-related factors in such patients according to their status for the T790M resistance mutation of EGFR.We identified 25 patients with EGFR mutation-positive NSCLC who were treated with nivolumab. Whole-exome sequencing of tumor DNA was carried out to identify gene alterations. Efficacy of nivolumab tended to increase as the PD-L1 expression level increased with cutoff values of 10% and 50%.The proportion of tumors with a PD-L1 level of10% or50% was higher among T790M-negative patients than among -positive patients. Nivolumab responders had a significantly higher CD8+ TIL density and nonsynonymous mutation burden. T790M-negative patients with EGFR mutation-positive NSCLC are more likely to benefit from nivolumab after EGFR-TKI treatment, possibly as a result of a higher PD-L1 expression level., 研究種目：若手研究(B);  研究期間：2016～2017;   課題番号：16K21506;   研究分野：臨床腫瘍学;   科研費の分科・細目：, application/pdf},
 title = {driver遺伝子異常肺癌に対する分子標的薬の耐性化と、抗PD1抗体の有効性},
 year = {2018},
 yomi = {ハヤシ, ヒデトシ}
}